Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals' Total Current Liabilities history spans 15 years, with the latest figure at $10.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 52.02% year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Dec 2025, up 52.02%, and an annual FY2025 reading of $10.5 million, up 52.02% over the prior year.
  • Total Current Liabilities for Q4 2025 was $10.5 million at Fennec Pharmaceuticals, up from $9.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $10.5 million in Q4 2025, with the low at $848000.0 in Q2 2021.
  • Average Total Current Liabilities over 5 years is $5.6 million, with a median of $4.6 million recorded in 2022.
  • Year-over-year, Total Current Liabilities crashed 73.42% in 2021 and then soared 258.14% in 2022.
  • Tracing FENC's Total Current Liabilities over 5 years: stood at $2.0 million in 2021, then soared by 128.85% to $4.6 million in 2022, then skyrocketed by 63.88% to $7.6 million in 2023, then fell by 8.39% to $6.9 million in 2024, then soared by 52.02% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Total Current Liabilities are $10.5 million (Q4 2025), $9.8 million (Q3 2025), and $8.4 million (Q2 2025).